BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...million at a price valuing the company at more than $3 billion; and CureVac N.V. (NASDAQ:CVAC...
BioCentury | Sep 5, 2020
Product Development

Moderna pushes for diverse Phase III as COVID-19 vaccine program nears enrollment target

...enrollment this month. Meanwhile, other vaccine developers provided updates on their programs this week. CureVac N.V. (NASDAQ:CVAC) is...
BioCentury | Aug 21, 2020
Product Development

EC looks to CureVac for first mRNA COVID-19 vaccine deal

...three other candidates, and a therapy from CalciMedica shows promise in severe COVID-19 patients.CureVac N.V. (NASDAQ:CVAC...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...treat cancer and orphan and infectious diseases.The pair of IPOs follow that of CureVac N.V. (NASDAQ:CVAC...
BioCentury | Aug 15, 2020
Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

...selling 13.3 million shares at $16, the top end of its proposed range, CureVac N.V. (NASDAQ:CVAC...
BioCentury | Aug 14, 2020
Finance

Non-European venture investment in European biotech is on the rise

...Postmoney Valuation of the Year”). CureVac N.V. (NASDAQ:CVAC...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...steps could include optimizing the vaccine to improve potency. Immutep Ltd. and Neopharm Group have CVac...
BioCentury | Jan 5, 2017
Clinical News

CV-301: Ph I/II started

...BioCentury, Oct. 10, 2011 ). Bavarian Nordic A/S (CSE:BAVA), Copenhagen, Denmark Product: CV301, CV-301 , CVAC-301...
...PFS), objective response rate (ORR) and duration of response Status: Phase I/II started Milestone: NA Julian Zhu CV-301 CVAC-301 Bavarian...
BioCentury | May 25, 2015
Clinical News

CVac: Phase II final data

...Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Product: CVac Business: Cancer Molecular target: Mucin 1 (MUC1...
...Milestone: NA Prima reported final data from the open-label, international Phase II CAN-003 trial evaluating CVac...
...n=20), median OS has not yet been reached after 42 months of follow-up in the CVac...
BioCentury | May 21, 2015
Clinical News

Prima posts big gain on CVac's survival trend

...its primary progression-free survival (PFS) endpoint in 2013. In the additional analysis, Prima said its CVac...
...trial's primary efficacy endpoint was PFS. In 2013, there were no observed differences between the CVac...
...for first remission patients favored the observation arm compared to CVac, whereas median PFS favored CVac...
Items per page:
1 - 10 of 46